Wuhan Hvsen (China) Performance
| 300871 Stock | 11.40 0.01 0.09% |
On a scale of 0 to 100, Wuhan Hvsen holds a performance score of 12. The firm maintains a market beta of -0.66, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Wuhan Hvsen are expected to decrease at a much lower rate. During the bear market, Wuhan Hvsen is likely to outperform the market. Please check Wuhan Hvsen's market risk adjusted performance, semi deviation, coefficient of variation, as well as the relationship between the mean deviation and downside deviation , to make a quick decision on whether Wuhan Hvsen's historical returns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Wuhan Hvsen Biotechnology are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Wuhan Hvsen sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Forward Dividend Yield 0.0237 | Payout Ratio 1.2068 | Last Split Factor 1.5:1 | Forward Dividend Rate 0.27 | Ex Dividend Date 2024-05-29 |
1 | Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com | 08/29/2024 |
| Begin Period Cash Flow | 278.6 M |
Wuhan |
Wuhan Hvsen Relative Risk vs. Return Landscape
If you would invest 842.00 in Wuhan Hvsen Biotechnology on August 28, 2024 and sell it today you would earn a total of 299.00 from holding Wuhan Hvsen Biotechnology or generate 35.51% return on investment over 90 days. Wuhan Hvsen Biotechnology is generating 0.5938% of daily returns and assumes 3.7325% volatility on return distribution over the 90 days horizon. Simply put, 33% of stocks are less volatile than Wuhan, and 89% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Wuhan Hvsen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Wuhan Hvsen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Wuhan Hvsen Biotechnology, and traders can use it to determine the average amount a Wuhan Hvsen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1591
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 300871 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.73 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.59 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Wuhan Hvsen is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Wuhan Hvsen by adding it to a well-diversified portfolio.
Wuhan Hvsen Fundamentals Growth
Wuhan Stock prices reflect investors' perceptions of the future prospects and financial health of Wuhan Hvsen, and Wuhan Hvsen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Wuhan Stock performance.
| Return On Equity | -0.0312 | ||||
| Return On Asset | -0.0029 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 2.33 B | ||||
| Shares Outstanding | 165.77 M | ||||
| Price To Book | 1.33 X | ||||
| Price To Sales | 1.69 X | ||||
| Revenue | 1.02 B | ||||
| Gross Profit | 222.75 M | ||||
| EBITDA | 150.08 M | ||||
| Net Income | 16.78 M | ||||
| Total Debt | 240.32 M | ||||
| Book Value Per Share | 8.62 X | ||||
| Cash Flow From Operations | 92.92 M | ||||
| Earnings Per Share | (0.28) X | ||||
| Total Asset | 2.98 B | ||||
| Retained Earnings | 341.94 M | ||||
About Wuhan Hvsen Performance
By analyzing Wuhan Hvsen's fundamental ratios, stakeholders can gain valuable insights into Wuhan Hvsen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Wuhan Hvsen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Wuhan Hvsen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Wuhan Hvsen is entity of China. It is traded as Stock on SHE exchange.Things to note about Wuhan Hvsen Biotechnology performance evaluation
Checking the ongoing alerts about Wuhan Hvsen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Wuhan Hvsen Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Wuhan Hvsen appears to be risky and price may revert if volatility continues | |
| About 61.0% of the company shares are owned by insiders or employees |
- Analyzing Wuhan Hvsen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Wuhan Hvsen's stock is overvalued or undervalued compared to its peers.
- Examining Wuhan Hvsen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Wuhan Hvsen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Wuhan Hvsen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Wuhan Hvsen's stock. These opinions can provide insight into Wuhan Hvsen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Wuhan Stock analysis
When running Wuhan Hvsen's price analysis, check to measure Wuhan Hvsen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Wuhan Hvsen is operating at the current time. Most of Wuhan Hvsen's value examination focuses on studying past and present price action to predict the probability of Wuhan Hvsen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Wuhan Hvsen's price. Additionally, you may evaluate how the addition of Wuhan Hvsen to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |